Short-term vasodilator effect of captopril in patients with severe mitral regurgitation is parasympathetically mediated.
BACKGROUND
Few data exist regarding the effects of angiotensin converting enzyme inhibitors in patients with regurgitant valvular lesions. We postulated an immediate improvement in cardiac performance with captopril in mitral regurgitation, which, in a hemodynamically compensated group of patients, might be mediated through parasympathetic vasodilation rather than through blockade of angiotension converting enzyme.


RESULTS
Hemodynamics were examined before and 90 minutes after oral captopril (25-50 mg) in 18 patients (mean age, 31 years) with chronic, severe mitral regurgitation in New York Heart Association functional class II and III. One group of patients was given captopril alone (group 1, n = 9) and a second group was given captopril plus atropine 0.04 mg/kg i.v. (group 2, n = 9). Captopril alone (group 1) produced decreases in heart rate (90-81 beats/min, p less than 0.001), mean arterial pressure (90-73 mm Hg, p less than 0.001), systemic resistance (28-23 Wood units, p = 0.068), and pulmonary wedge pressure (19-14 mm Hg, p less than 0.001). There was no improvement in either arteriovenous oxygen difference or thermodilution cardiac output; in fact, the latter slightly declined (3.45-3.35 l/min, p = 0.002). Pretreatment with atropine (group 2) diminished the effects of captopril on heart rate (107-103 beats/min, p = 0.065 for atropine effect by two-way ANOVA), mean arterial pressure (88-82 mm Hg, p = 0.01 for atropine effect), and systemic resistance (26-27 Wood units, p = 0.04 for atropine effect).


CONCLUSIONS
In patients with chronic, severe mitral regurgitation, captopril reduced systemic arterial and left ventricular filling pressures but did not immediately augment cardiac output as expected. Furthermore, the modest systemic vasodilator effect of captopril was parasympathetically mediated.
Cardiology Department, Baragwanath Hospital, Johannesburg, South Africa.
T
T
Wisenbaugh
R
R
Essop
P
P
Sareli
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001285:Atropine / Q000494:pharmacology; D002216:Captopril / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008944:Mitral Valve Insufficiency / Q000188:drug therapy* / Q000503:physiopathology; D010275:Parasympathetic Nervous System / Q000502:physiology*; D011292:Premedication; D012214:Rheumatic Heart Disease / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D014664:Vasodilation / Q000187:drug effects*
D000806:Angiotensin-Converting Enzyme Inhibitors; D001285:Atropine; D002216:Captopril